263 related articles for article (PubMed ID: 25584070)
1. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.
Hadden RD; Marreno F
Ther Adv Neurol Disord; 2015 Jan; 8(1):14-9. PubMed ID: 25584070
[TBL] [Abstract][Full Text] [Related]
2. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs.
Markvardsen LH; Harbo T
J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163
[TBL] [Abstract][Full Text] [Related]
4. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
5. Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions.
Gingele S; Koch M; Saparilla AC; Körner GM; von Hörsten J; Gingele M; Seeliger T; Konen FF; Hümmert MW; Neyazi A; Stangel M; Skripuletz T
Ther Adv Neurol Disord; 2021; 14():17562864211009100. PubMed ID: 33948119
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
7. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
Markvardsen LH; Christiansen I; Andersen H; Jakobsen J
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
Goyal NA; Karam C; Sheikh KA; Dimachkie MM
Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
Harbo T; Andersen H; Jakobsen J
Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
14. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases.
Sala TP; Crave JC; Duracinsky M; Lepira Bompeka F; Tadmouri A; Chassany O; Cherin P
Autoimmun Rev; 2018 Sep; 17(9):873-881. PubMed ID: 30005853
[TBL] [Abstract][Full Text] [Related]
17. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
20. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
